alexa Addressing barriers to insulin therapy: the role of insulin pens.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Magwire ML

Abstract Share this page

Abstract Despite the fundamental role of insulin therapy in diabetes management, many patients and some clinicians may resist insulin initiation due to concerns about its complexity or a general resistance to injections. Many patients' concerns about insulin initiation may stem from perceptions about the pain and inconvenience of using vials and syringes for delivering insulin. However, insulin pen devices offer an easier method for insulin administration that is more accurate, less painful, and more discreet compared with vials and syringes. Advances in insulin pen technology have enhanced their utility by increasing their accuracy, reducing the injection force required, and incorporating mechanisms to store the dose, time, and date of previous insulin injections. Substantial evidence demonstrates that insulin pen devices are preferred by both patients and clinicians and have the potential to improve adherence, enhance quality of life, reduce the risk of hyperglycemia, and decrease costs. Ultimately, the advantages of insulin pens may reduce resistance to initiating and adhering to insulin therapy. Because insulin pens are underused in the United states compared with in other countries, it is critical that clinicians understand the potential benefits of insulin pens and communicate them to their patients. (C) 2011 Lippincott Williams & Wilkins, Inc. This article was published in Am J Ther and referenced in Journal of Diabetes & Metabolism

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version